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The role of quantitative D-dimer levels in the follow-up and
differential diagnosis of pulmonary thromboembolism and
community-acquired pneumonia
Ayhan VAROL, Nurdan KÖKTÜRK, Hatice KILIÇ, Müge AYDOĞDU, Numan Nadir EKİM

Aim: To identify the quantitative D-dimer levels in pulmonary thromboembolism (PTE) and hospitalized-community
acquired pneumonia (CAP) patients, and to determine the alteration of D-dimer levels with anticoagulant or antibacterial
therapy. It is not well known that the quantitative analysis of D-dimer has a role in the differential diagnosis of PTE from
other diseases.
Materials and methods: Serum D-dimer levels were measured and compared prospectively with a latex-enhanced
immunoturbidimetric method at admission, before initiating any antibiotic or anticoagulant therapy and then at days 3,
10, and 30 of treatment in PTE and CAP patients.
Results: A total of 80 patients (45 PTE and 35 CAP), with a mean age of 61 ± 16 years, were included in the study. Mean
D-dimer levels at admission were significantly higher in the PTE group than in the CAP group (3388 ± 2080 vs. 1190 ±
1089 μ/L, P = 0.001). After initiating the anticoagulant therapy, a significant decrease in D-dimer levels was identified
in the PTE group, but not in the CAP group, on day 3 (678 ± 652 μ/L vs. 724 ± 907 μ/L). In the receiver operating
characteristic curve analysis, D-dimer levels of >1700 μ/L were statistically significant as a cut-off value for the diagnosis
of PTE (AUC: 0.820; 95% CI: 0.73-0.92).
Conclusion: Although serum quantitative D-dimer levels cannot be used solely for the differential diagnosis of CAP
and PTE, they might be helpful in making the decision to perform further diagnostic methods. Since D-dimer levels
decreased more rapidly and significantly in PTE than CAP cases, they might be used as a marker for monitoring the
treatment response in patients with PTE, but this must be proven with more comprehensive studies.
Key words: D-dimer, pulmonary thromboembolism, community-acquired pneumonia

Toplumda gelişen pnömoni ve pulmoner tromboembolizm ayırıcı tanısında ve
pulmoner tromboembolizm takibinde, kantitatif D-dimer seviyelerinin rolü
Amaç: D-dimer kantitatif analizinin pulmoner tromboemboliyi (PTE) diğer hastalıklardan ayırmadaki rolü iyi
bilinmemektedir. Bu çalışmada PTE’si ve hospitalizasyon gerektiren toplum kökenli pnömonisi (TKP) olan hastalarda
kantitatif D-dimer değerlerinin ve tedavi ile bu değerlerdeki değişimin belirlenmesi amaçlandı.
Yöntem ve gereç: Serum D-dimer düzeyleri, başlangıçta herhangi bir antibiyotik veya antikoagülan tedavi başlamadan
önce lateks takviyeli immunotürbidimetrik yöntemle ölçüldü ve her iki grupta karşılaştırıldı. Daha sonra 3.gün, 10.gün
ve 1.ayda PTE ve TKP’si olan hastalarda serum D-dimer düzeyleri ölçülerek, karşılaştırıldı.
Bulgular: Ortalama yaşları 61 ± 16 olan, toplam 80 hasta (45 PTE ve 35 TKP) çalışmaya alındı. Başlangıçtaki ortalama
D-dimer düzeyleri PTE grubunda, TKP grubuna göre anlamlı olarak daha yüksek bulundu (3388 ± 2080 vs 1190 ±
1085 μ/L, P = 0,001). Antikoagülan tedavinin başlangıcından sonra, PTE grubunda D-dimer düzeylerinde anlamlı bir
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düşme belirlenirken, TKP grubunda bu düşüş izlenmedi (3.gün ölçümlerinde 678 ± 652 μ/L vs 724 ± 907 μ/L ). ROC
eğrisi analizinde D-dimer seviyesi >1700 μ/L, PTE teşhisi için cut-off değeri olarak anlamlı bulundu (AUC: 0,820; % 95
CI: 0,73 - 0,92).
Sonuç: Serum kantitatif D-dimer düzeyi PTE ve TKP’nin ayırıcı teşhisi için tek başına kullanılamaz ancak daha ileri
tanısal metodların uygulama kararını vermede yardımcı olabilir. D-dimer seviyesi TKP’ye göre PTE’de çok daha hızlı
ve istatistiksel olarak anlamlı düştüğü için PTE’li hastalarda tedavi yanıtını izlemede kullanılabilir. Fakat bu konu daha
geniş çaplı çalışmalar ile desteklenmelidir.
Anahtar sözcükler: D-dimer, pulmoner tromboembolizm, toplumda gelişen pnömoni

Introduction
Pulmonary thromboembolism (PTE) remains an
important cause of morbidity and mortality in the
world, with an overall annual incidence of 60-70
cases in 100,000. It is the most common underlying
cause of unexpected in-hospital deaths. Its mortality
is 2%-8% in appropriately diagnosed and treated
patients, but it can be as high as 25%-30% if there is a
delay or failure in diagnosis and treatment (1).
PTE is a disease that is relevant in all disciplines of
medicine. However, there are difficulties in diagnosis
due to the inadequate evaluation of risk factors and
various nonspecific symptoms usually overlapping
or mimicking other diseases (2). It can be frequently
misdiagnosed as pneumonia. Especially in patients
presenting with fever, both anticoagulants and
antibiotics are usually initiated as treatment until an
exact diagnosis can be made.
D-dimer is a specific fibrin degradation product
indicating plasmin-associated fibrin breakdown.
In the suspicion of PTE, a D-dimer assay has an
important role in yielding a diagnosis. The D-dimer
assay has high sensitivity but low specificity for the
diagnosis of PTE. Increased levels may be identified
in cases such as pneumonia, malignancies, pregnancy,
old age, chronic renal failure, liver failure, major
trauma, recent operation, and hospitalization (3).
During pneumonia, vascular congestion
develops and the alveolar cavity fills with fibrin.
Due to enzymatic degradation of this fibrin by the
fibrinolytic system, fibrin degradation products can
be released into the circulation. Therefore, being one
of the fibrin degradation products, D-dimer levels
can be increased in pneumonia (4,5). It has previously
been shown in many studies that when the severity of
pneumonia increases, D-dimer levels also increase in
parallel (6-9).
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A qualitative D-dimer assay is important in
excluding PTE or deciding on advanced methods for
a diagnostic workup. However, it is not well known
that quantitative analysis of D-dimer has a role in
differentiating PTE from other diseases that cause
positive D-dimer levels. Aside from this, it is also
uncertain if the follow-up of D-dimer levels has a role
in PTE.
Therefore, in this study, the aim was to evaluate the
quantitative D-dimer levels in PTE and hospitalizedcommunity acquired pneumonia (CAP) patients and
to determine the alteration in D-dimer levels with
anticoagulant or antibacterial treatment.
Materials and methods
This study was performed in a pulmonary department
of a university hospital from January 2007 to January
2009. The ethics committee of the institution approved
the study and the procedures performed in this study
were in accordance with the Helsinki Declaration.
All of the patients gave informed consent.
Patient selection
Patients who were >18 years old were included in
the study prospectively and consecutively if they
met the inclusion criteria, provided that they had no
exclusion criteria.
Inclusion criteria
1. Being diagnosed as a PTE patient by at least
one of these methods: ventilation/perfusion
lung scintigraphy (V/Q lung scan), multislice
computed tomography (CT), or lower extremity
venous Doppler ultrasonography (USG; in case of
high clinical suspicion of PTE and nondiagnostic
V/Q scintigraphy, if multislice CT could not be
performed).
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2. Being diagnosed as a CAP patient according to
the criteria of the American Thoracic Society
(ATS) guidelines for pneumonia (10).

not intensive care unit treatment according to ATS
criteria were accepted for the study.

Exclusion criteria

Patients with the diagnosis of PTE or CAP were
included in the study. The following data were
recorded prospectively from all of the patients:
demographic characteristics (age, sex); symptoms
and signs at admission; predisposing factors for
PTE (immobility, deep venous thrombosis, previous
PTE history, family history, recent travel history,
oral contraceptive use, recent surgery, obesity,
chronic obstructive pulmonary disease (COPD), and
atherosclerotic heart disease); and additional risk
factors for CAP (COPD, diabetes mellitus, etc.).

1. Having one of these diagnoses:
a. Acute liver failure
b. Malignancy
c. Pregnancy
d. Renal failure
e. Sepsis syndrome
2. Fulfilling the criteria of CAP but also having clinical
symptoms of deep venous thromboembolism
(DVT) and PTE.
3. Unwilling to be included in the study.
Definitions
PTE was diagnosed if patients had (1,11,12):
1. Clinical suspicion of PTE and high probability
V/Q lung scan or,
2. Moderate probability V/Q lung scan and DVT
diagnosed with lower extremity venous Doppler
USG or,
3. Pulmonary thrombus identified with multislice
pulmonary CT.
PTE was classified as follows (11,13,14):
High-risk PTE (previously known as massive
PTE): Patients with the diagnosis of PTE being
clinically hypotensive or having shock, and/or having
right ventricular dysfunction in echocardiography
and positive biomarkers of acute myocardial injury.
Intermediate-risk PTE (previously known as
submassive PTE): Patients with the diagnosis of PTE
having no shock or hypotension but signs of right
ventricular dysfunction in echocardiography, and/or
positive biomarkers of acute myocardial injury.
Low-risk PTE (previously known as nonmassive
PTE): Patients with the diagnosis of PTE having
no shock or hypotension, no right ventricular
dysfunction, and no signs of myocardial injury.
CAP: Patients fulfilling the clinical, radiological,
and laboratory criteria of the ATS guidelines for
CAP in adults were diagnosed as having CAP (10).
The CAP patients who required hospitalization but

Settings

Laboratory workup
Upon admission, chest X-ray (infiltration, diaphragm
elevation, linear atelectasis, pleural effusion,
blunt costophrenic sinus, hilar enlargement, and
cardiomegaly), arterial blood gas analysis (PaO2,
PaCO2, pH, and SaO2), D-dimer level measurements,
and routine laboratory tests (hemoglobin, leukocyte
count, platelet count, and hepatic function tests) were
performed in all of the patients. Electrocardiograms
(ECGs) were recorded in all of the patients.
Echocardiography was performed in only high-risk
and intermediate-risk PTE patients.
D-dimer assay
D-dimer levels were measured with the Sysmex®
CA-7000 System (Germany) with a latex-enhanced
immunoturbidimetric method named D-Dimer
Plus. Values above 500 μ/L were evaluated as positive.
This method of D-dimer analysis was chosen for the
study since it has 91%-93.3% sensitivity, 38%-45%
specificity, and 91%-99% negative predictive value.
Moreover, it was more cost-effective than the ELISA
method and rapid results could be obtained.
D-dimer levels were measured within the first 24
h prior to initiating anticoagulant therapy in patients
with PTE, and prior to antibacterial treatment in
patients with CAP. After the initiation of treatment,
D-dimer levels were studied on days 3, 10, and 30.
Patients with clinical improvement were discharged
from the hospital. Patients with PTE were called and
questioned about recurrence at the end of the first
year. Patients in the CAP group were discharged
after being clinically stable, and they completed their
641
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oral antibiotic therapy at home. They were called
for an outpatient clinic exam the first month after
hospitalization.
Statistical analysis
SPSS 11.5 for Windows (SPSS, Chicago, IL, USA) was
used for analyses. Descriptive statistics were given as
means ± standard deviations (SD) for continuous
variables and as percentages (%) for categorical
variables. Continuous variables were compared using
Student’s t-test for normally distributed variables
and the Wilcoxon rank-sum test for nonnormally
distributed variables. The chi-square test or Fisher’s
exact test was used to compare categorical variables.
Repeating measurements among the groups were
analyzed with the Friedman test or repeated measures

analysis of variance (ANOVA). When statistically
significant results were obtained with the Friedman
test or repeated measures ANOVA, Bonferroni
correction multiple comparison tests or Friedman
multiple comparison tests were consequently
performed. The cut-off point for D-dimer levels was
sought with receiver operating characteristics (ROC)
curve analysis. P < 0.05 was accepted as statistically
significant.
Results
A total of 80 patients, with a mean age of 61 ± 16
years, were included in the study. The study design
and distribution of the patients are summarized in
Figure 1.
90 patients with the
diagnosis of PTE and
CAP were recruited
for the study

2 patients excluded
due to multiple organ
failure

4 patients excluded
due to underl ying
malignancy

4 patients declining
to be included in the
study

A total of 80 patients
included in the study

PTE
N = 45
(20 male, 25
female)

CT Pulmonary
angiography
N = 22

CAP
N = 35
(19 male, 16
female)

V/Q lung scintigraphy
N = 23

High probability
N = 19

Moderate probability
N=4

Figure 1. Study design and distribution of the patients.
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Among the 80 patients, 45, with a mean age 61 ±
17 years, were diagnosed with PTE, and 35, with a
mean age 62 ± 15 years, were diagnosed with CAP.
Among the PTE group, 1 patient was classified with
high-risk PTE, 13 patients with intermediate-risk
PTE, and 31 patients with low-risk PTE. Only one
high-risk PTE patient received thrombolytic therapy;
all of the other PTE patients received standard and
low molecular weight heparin as an anticoagulant
treatment. The demographic characteristics, risk
factors, comorbidities, chest X-ray findings, and
arterial blood gas analysis on admission of the 2
groups were compared and are summarized in Table

1. Where symptoms on admission were concerned,
rates of fever, cough, and sputum were significantly
higher in the CAP group, and swelling of the leg was
significantly higher in the PTE group (P < 0.05).
No significant difference was identified among the
routine laboratory parameters of hemoglobin level,
white blood cell and platelet count, and biochemical
tests.
In the electrocardiographic evaluation, the inverse
T wave was the most common (30 patients, 66.7%)
and sinus tachycardia (15 patients, 33.3%) was the
second most common finding in the PTE group. The
S1Q3T3 pattern was more frequent in the PTE group

Table 1. Comparison of the demographic factors, comorbidities, risk factors, chest X-ray findings, and
arterial blood gas analysis of the patients with PTE and CAP on admission.
PTE (n = 45)
mean ± SD

Pneumonia (n = 35)
mean ± SD

P

61 ± 17

62 ± 15

0.676

Sex (female), n (%)

24 (53)

15 (43)

0.241

Smoking, n (%)

17 (39)

21 (60)

0.048

Risk factors and comorbidities
Obesity, n (%)
Travel, n (%)
Immobilization, n (%)
COPD, n (%)
Atherosclerotic heart disease, n (%)
Diabetes mellitus, n (%)
Systemic hypertension, n (%)
Previous VTE, n (%)
Recent surgery, n (%)
Oral contraceptive, n (%)
Trauma, n (%)

11 (24)
7 (16)
14 (31)
1 (2)
10 (23)
4 (9)
16 (36)
13 (29)
9 (21)
2 (5)
7 (16)

11 (31)
1 (3)
1 (3)
12 (34)
9 (26)
6 (17)
15 (43)
0 (0)
0 (0)
0 (0)
0 (0)

0.328
0.062
0.001
0.001
0.504
0.324
0.332
0.001
0.004
0.307
0.013

Chest X-ray findings
Infiltration, n (%)
Diaphragm elevation, n (%)
Linear atelectasis, n (%)
Blunt costophrenic sinus, n (%)
Pleural effusion, n (%)
Hilar enlargement, n (%)

10 (22)
20 (44)
8 (18)
17 (38)
2 (4)
15 (33)

35 (100)
0
0
11 (31)
5 (14)
8 (23)

0.001
0.001
0.007
0.363
0.126
0.219

Arterial blood gas analysis results
pH
PaO2
PaCO2
HCO3
SaO2 (%)

7.44 ± 0.03
64 ± 13
30 ± 5
21 ± 2
92 ± 5

7.42 ± 0.05
57 ± 10
35 ± 8
23 ± 4
89 ± 8

0.270
0.056
0.005
0.041
0.186

Parameter

Demographic factors
Age (years)
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than in the CAP group, as expected [in 9 PTE patients
(20%) and in 2 CAP patients (5.7%), P < 0.05].
Echocardiography was performed in 30 patients
in the PTE group. Right ventricular dilatation and/
or hypokinesia were observed in 13 patients and
paradoxical interventricular septal movement was
observed in 4 patients. Pulmonary arterial pressure
was measured in 17 patients as 46 ± 19 mmHg and
ejection fraction was measured as 61% ± 12.
D-dimer levels on admission (day 0) were
significantly higher in the PTE group (3388 ± 2080
μ/L) than in the CAP group (1190 ± 1089 μ/L; P =
0.001). No statistical difference was observed in the
following days (Table 2). A steep decline in D-dimer
levels between day 0 and day 3 was identified in the
PTE group but not in the CAP group (Figure 2).
When the D-dimer level decline was evaluated in each
group under anticoagulant or antibacterial therapy,

a statistically significant difference was identified
in only the PTE group. The differences in D-dimer
levels between day 0 and day 3, day 0 and day 10,
and day 0 and day 30 were statistically significant (P
= 0.001 for all of the variables). No such significant
difference was identified within the CAP group.
A cut-off value for D-dimer levels was investigated
with ROC curve analysis for the differentiation of
PTE from CAP. A value of ≥1700 μ/L at day 0 was
significant for the PTE group. The area under curve
(AUC) of the ROC curve was 0.820 (95% CI: 0.730.92). The D-dimer level at day 0 was ≥1700 μ/L in
36 (80%) of the PTE patients (P = 0.001) (Figure
3). The sensitivity of the D-dimer test at ≥1700 μ/L
for indicating the diagnosis of PTE was 80%, and
specificity was 71%. In the CAP group, a negative
ROC curve was obtained; in other words, with the
increase in D-dimer levels, the probability of CAP
diagnosis decreased.

Table 2. D-dimer levels in follow-up for CAP and PTE.
D-dimer levels
(μ/L)

PTE
(mean ± SD)

Pneumonia
(mean ± SD)

P

Day 0

3388 ± 2080

1190 ± 1089

0.001

Day 3

678 ± 652

724 ± 907

0.790

Day 10

606 ± 655

518 ± 517

0.482

Day 30

251 ± 289

337 ± 526

0.352

D-dimer levels in PTE and CAP

4000
3500

D-Dimer

3000
2500
2000
1500
1000
500
0

Day 10

Day 30

PTE

Day 0
3388

Day 3
678

606

251

CAP

1190

724

518

337

Figure 2. The D-dimer values by day in PTE and CAP patients. A steep decline of
D-dimer values between days 0 and 3 was identified in the PTE group but
not in the CAP group (P = 0.001).
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1.0

ROC curve

Sensitivity

0.8
0.5

0.3
0.0
0.0

0.3

0.5
Specifity

0.8

1.0

Figure 3. ROC curve analysis of D-dimer levels on admission in
the PTE group. The AUC of the ROC curve was 0.820
(95% CI: 0.73-0.92).

In the PTE group, 2 patients died due to multiple
organ failure (4.4%). Their D-dimer levels at day 30
of their hospitalization were also high. None of the
patients in the CAP group developed multiorgan
failure.
Patients with the diagnosis of PTE were discharged
from the hospital when clinical and laboratory
responses to anticoagulant treatment were obtained.
At the end of the first year, those patients were called
and questioned about recurrence. No recurrence was
identified in any of the patients. Lifelong anticoagulant
therapy was planned for the patients with a history
of previous venous thromboembolism (VTE). CAP
patients were discharged from the hospital when
clinic and laboratory responses were obtained. Their
mean length of stay was 10.5 days. At their 1-month
follow-ups, no complications were observed.
Discussion
This study pointed out that although serum D-dimer
levels at admission increased in both PTE and CAP
patients, higher levels, i.e. ≥1700 μ/L, were usually
found in the PTE patients. Since the D-dimer levels
decreased rapidly within days in the PTE patients
under appropriate therapy, monitorization of the
quantitative D-dimer levels might be useful for
evaluating the treatment response of PTE patients.
To the best of our knowledge, this is the first study
in the literature in which quantitative D-dimer levels
were evaluated and compared in patients with PTE
and CAP.

Plasma D-dimer is formed by the degradation of
fibrin by the endogenous fibrinolytic system. It is one
of the best laboratory markers of coagulation activity.
In addition to being a marker of prothrombotic
states, it might also designate thromboembolism
risk (15). It has been shown previously that in VTE,
the D-dimer levels increase 8 times when compared
with the control group. The peak D-dimer level was
found to be correlated with the extent of thrombosis
(16). Fraser et al. confirmed in their study with direct
magnetic resonance imaging that D-dimer levels are
correlated with the volume and surface area of the clot
(17). Hayashi et al. also found that increased D-dimer
levels are correlated with the thrombus volume in left
atrial thrombosis (18). In our study, the number of
high-risk and intermediate-risk PTE patients was not
sufficient to make a statistical comparison.
CAP is one of the most important diseases that
must be considered in the differential diagnosis of
PTE. In addition to similar symptoms and clinical
findings, laboratory tests are not usually helpful for
differentiating the diseases. Depending on these
similarities, it is generally difficult to make the
differential diagnosis of these 2 conditions.
In recent studies, it was supported that both
intravascular and extravascular coagulation correlate
with acute and chronic lung injury (19-21). During
pneumonia, vascular congestion develops and fibrin
fills out the alveolar cavity. After the enzymatic
degradation of fibrin by the fibrinolytic system, fibrin
degradation products like D-dimer can be released
into the circulation (4,5). It has been shown previously
in many studies that when the severity of pneumonia
increases, the D-dimer levels also increase in parallel
(6-9). Shorr et al. and Pettila et al. found a correlation
between coagulation system activation markers such
as D-dimer levels and cytokines like interleukin-6 in
critically ill patients (22,23). In our study, pneumonia
cases were severe enough to require hospitalization,
but pneumonia severity index scoring was not done,
which is a limitation of this study. Although patients’
mean D-dimer level was >500 μ/L until day 10, it
turned out to be normal at their 1-month follow-up.
Castro et al. studied the diagnostic role of D-dimer
levels in 52 suspected PTE and 19 CAP cases. They
classified the patients into 2 groups according to V/Q
scintigraphy as high probability and low probability.
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They found that D-dimer levels in the highprobability group were significantly higher than in
the low-probability group. Although no statistically
significant difference was identified between the
mean D-dimer levels of the CAP group and the lowprobability PTE group, a significant difference was
recognized between the CAP group and the highprobability PTE group (24). Similarly, in our study,
D-dimer levels at admission were significantly higher
in the PTE group (3388 ± 2080 μ/L) than in the CAP
group (1190 ± 1089 μ/L; P = 0.001).
Couturaud et al. evaluated the rate of decline in
D-dimer levels and the sensitivity of this test at the
end of the first 24 h of anticoagulant therapy in VTE
patients (25). They found that in patients receiving
heparin treatment, D-dimer levels decreased 25% at
the end of the first 24 h and the sensitivity of D-dimer
test regressed from 95.6% to 89.4%. D-dimer levels
were decreased by 40% at the end of 48 h. In our study,
D-dimer levels decreased by 80% in the PTE group, but
no such decrease was identified in the CAP group. This
reduction may lead to the assumption that the diagnosis
of PTE was correct and the treatment was effective.
Recurrence can be identified in 5%-23% of cases of
VTE despite appropriate treatment. The highest risk
occurs within 6-12 months after cessation of treatment
(26,27). Recent prospective observational studies
showed that D-dimer levels have a predictive value
for the recurrence of PTE (28-31). When compared
to patients with transient risk factors of VTE, those
with permanent risk factors and idiopathic VTE have
higher D-dimer levels and a subsequent recurrence

risk. In the PROLONG study, D-dimer levels were
studied 1 month after the cessation of anticoagulant
therapy (30). Anticoagulation was not continued in
patients with normal D-dimer levels. Patients with
high D-dimer levels were randomized either for
continuing or not continuing anticoagulant therapy.
After the completion of a 1.4-year follow-up period,
the approximate recurrence risk was measured as
6.2% among patients with normal D-dimer levels
that were not continuing anticoagulant therapy,
as 15% among those with high D-dimer levels that
were not continuing therapy, and as 2.9% among
those with high D-dimer levels that were continuing
anticoagulant therapy (30). In this study, we also
hypothesized that recurrence could occur in patients
after completion of the anticoagulant therapy, but no
recurrence was identified in any of the patients at the
end of the first year.
This study had some limitations. It was a singlecenter study with a limited number of patients in a
specific local setting. However, the study findings
could serve as cornerstones for further multicenter
studies involving a larger number of patients.
In conclusion, although serum quantitative
D-dimer levels cannot be used solely for the
differential diagnosis of CAP and PTE, they might
be helpful in making the decision to use further
diagnostic methods. Since D-dimer levels decreased
more rapidly and significantly in PTE than in CAP
patients, they may be used as markers for monitoring
the treatment response in patients with PTE, but this
must be proved with more comprehensive studies.
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